Ipca Laboratories Ltd share Price Today

Pharmaceuticals company Ipca Laboratories announced Q3FY24 & 9MFY24 results:

Q3FY24 Financial Highlights:

• Standalone Net Total Income increased by 4% to Rs 1,523.72 crore.
• Consolidated Net Total Income surged by 32% to Rs 2,075.31 crore.
• Indian formulations income grew by 11% to Rs 779.61 crore.
• Exports Income rose by 1% to Rs 640.34 crore.
• Standalone EBITDA margin (before forex gain/loss and other income) stood at 18.55% in Q3FY24, compared to 15.77% in Q3FY23.
• Consolidated EBITDA margin (before forex gain/loss, other income, and exceptional items) stood at 16.12% in Q3FY24, compared to 15.00% in Q3FY23.
• Standalone Net Profit increased by 19% to Rs 136.94 crore.
• Consolidated Net Profit surged by 67% to Rs 179.88 crore.

9MFY24 Financial Highlights:

• Standalone Net Total Income grew by 6% to Rs 4,752.03 crore.
• Consolidated Net Total Income increased by 20% to Rs 5,777.88 crore.
• Indian formulations income rose by 12% to Rs 2,407.33 crore.
• Exports Income increased by 1% to Rs 1,976.32 crore.
• Standalone EBITDA margin (before forex gain/loss, other income, and Unichem acquisition cost) stood at 19.55% in 9MFY24, compared to 17.63% in 9MFY23.
• Consolidated EBITDA margin (before forex gain/loss, other income, Unichem acquisition cost, and exceptional items) stood at 17.34% in 9MFY24, compared to 16.64% in 9MFY23.
• Standalone Net Profit grew by 11% to Rs 465.65 crore.
• Consolidated Net Profit increased by 24% to Rs 487.76 crore.

Result PDF